{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T06:37:00Z","timestamp":1770359820191,"version":"3.49.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1124\/dmd.107.019265","type":"journal-article","created":{"date-parts":[[2007,11,30]],"date-time":"2007-11-30T01:49:10Z","timestamp":1196387350000},"page":"523-528","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"title":["CYP2C19 Inhibition: The Impact of Substrate Probe Selection on in Vitro Inhibition Profiles"],"prefix":"10.1016","volume":"36","author":[{"given":"Robert S.","family":"Foti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan L.","family":"Wahlstrom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.107.019265_bib1","series-title":"Goodman and Gilman\u2019s The Pharmacological Basis of Therapeutics","author":"Brunton","year":"2006"},{"key":"10.1124\/dmd.107.019265_bib2","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0009-9236(97)90114-4","article-title":"Validation of the five-drug \u201cPittsburgh cocktail\u201d approach for assessment of selective regulation of drug-metabolizing enzymes","volume":"62","author":"Frye","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.107.019265_bib3","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/sj.clpt.6100050","article-title":"Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the \u201ccocktail\u201d approach","volume":"81","author":"Fuhr","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.107.019265_bib4","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1046\/j.0306-5251.2001.01499.x","article-title":"Clinical relevance of genetic polymorphisms in the human CYP2C subfamily","volume":"52","author":"Goldstein","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.107.019265_bib5","doi-asserted-by":"crossref","first-page":"12496","DOI":"10.1074\/jbc.271.21.12496","article-title":"Identification of residues 99, 220, and 221 of human cytochrome P450 2C19 as key determinants of omeprazole activity","volume":"271","author":"Ibeanu","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.107.019265_bib6","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1023\/A:1007509324428","article-title":"Quantitative prediction of in vivo drug-drug interactions from in vitro data based on physiological pharmacokinetics: use of maximum unbound concentration of inhibitor at the inlet to the liver","volume":"17","author":"Kanamitsu","year":"2000","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.107.019265_bib7","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1046\/j.1365-2125.1999.00073.x","article-title":"CYP3A4 drug interactions: correlation of 10 in vitro probe substrates","volume":"48","author":"Kenworthy","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.107.019265_bib8","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s002280050673","article-title":"Drug-drug interactions of new active substances: mibefradil example","volume":"55","author":"Krayenb\u00fchl","year":"1999","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.107.019265_bib9","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1124\/dmd.106.010926","article-title":"CYP2C9 inhibition: impact of probe selection and pharmacogenetics on in vitro inhibition profiles","volume":"34","author":"Kumar","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.107.019265_bib10","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1124\/jpet.105.090928","article-title":"Enantiomer\/enantiomer interactions between the S- and R-isomers of omeprazole in human cytochrome P450 enzymes: major role of CYP2C19 and CYP3A4","volume":"315","author":"Li","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.107.019265_bib11","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1124\/dmd.31.5.606","article-title":"Impact of nonspecific binding to microsomes and phospholipid on the inhibition of cytochrome P4502D6: implications for relating in vitro inhibition data to in vivo drug interactions","volume":"31","author":"Margolis","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.107.019265_bib12","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1001\/jama.1990.03450210088038","article-title":"Torsades de pointes occurring in association with terfenadine use","volume":"264","author":"Monahan","year":"1990","journal-title":"JAMA"},{"key":"10.1124\/dmd.107.019265_bib13","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1124\/jpet.105.093229","article-title":"The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions","volume":"316","author":"Obach","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.107.019265_bib14","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1124\/dmd.105.008672","article-title":"The human intestinal cytochrome P450 \u201cpie.\u201d","volume":"34","author":"Paine","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.107.019265_bib15","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1021\/op049779d","article-title":"Preparation of optically pure esomeprazole and its related salts","volume":"10","author":"Raju","year":"2006","journal-title":"Organic Process Res Dev"},{"key":"10.1124\/dmd.107.019265_bib16","doi-asserted-by":"crossref","first-page":"4072","DOI":"10.1021\/jm0109107","article-title":"Analysis of selective regions in the active sites of human cytochromes P450, 2C8, 2C9, 2C18, and 2C19 homology models using GRID\/CPCA","volume":"44","author":"Ridderstr\u00f6m","year":"2001","journal-title":"J Med Chem"},{"key":"10.1124\/dmd.107.019265_bib17","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/S0022-3565(24)29631-2","article-title":"Identification of the human cytochromes p450 responsible for in vitro formation of R- and S-norfluoxetine","volume":"297","author":"Ring","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.107.019265_bib18","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2174\/1389200023337522","article-title":"Cytochrome P450 pharmacogenetics in drug development: in vitro studies and clinical consequences","volume":"3","author":"Rodrigues","year":"2002","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.107.019265_bib19","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1021\/bi00227a012","article-title":"Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily","volume":"30","author":"Romkes","year":"1991","journal-title":"Biochemistry"},{"key":"10.1124\/dmd.107.019265_bib20","doi-asserted-by":"crossref","first-page":"9497","DOI":"10.1074\/jbc.M312516200","article-title":"Structure of human microsomal cytochrome P450 2C8: evidence for a peripheral fatty acid binding site","volume":"279","author":"Schoch","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.107.019265_bib21","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1076-7460.2002.01422.x","article-title":"Rhabdomyolysis and statin therapy: relevance to the elderly","volume":"11","author":"Sica","year":"2002","journal-title":"Am J Geriatr Cardiol"},{"key":"10.1124\/dmd.107.019265_bib22","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1067\/mcp.2000.109519","article-title":"Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the \u201cCooperstown cocktail.\u201d","volume":"68","author":"Streetman","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.107.019265_bib23","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/S0090-9556(24)13672-0","article-title":"Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates","volume":"28","author":"Stresser","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.107.019265_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.abb.2004.05.015","article-title":"Active-site characteristics of CYP2C19 and CYP2C9 probed with hydantoin and barbiturate inhibitors","volume":"429","author":"Suzuki","year":"2004","journal-title":"Arch Biochem Biophys"},{"key":"10.1124\/dmd.107.019265_bib25","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1046\/j.1365-2125.1999.00914.x","article-title":"Ticlopidine decreases the in vivo activity of CYP2C19 as measured by omeprazole metabolism","volume":"47","author":"Tateishi","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.107.019265_bib26","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1021\/bi001678u","article-title":"Identification of human CYP2C19 residues that confer S-mephenytoin 4\u2032-hydroxylation activity to CYP2C9","volume":"40","author":"Tsao","year":"2001","journal-title":"Biochemistry"},{"key":"10.1124\/dmd.107.019265_bib27","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/nrd1851","article-title":"Predicting in vivo drug interactions from in vitro drug discovery data","volume":"4","author":"Wienkers","year":"2005","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/dmd.107.019265_bib28","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nature01862","article-title":"Crystal structure of human cytochrome P450 2C9 with bound warfarin","volume":"424","author":"Williams","year":"2003","journal-title":"Nature"},{"key":"10.1124\/dmd.107.019265_bib29","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1365-2125.2003.02047.x","article-title":"Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes","volume":"57","author":"Yasui-Furukori","year":"2004","journal-title":"Br J Clin Pharmacol"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624015988?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624015988?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.107.019265","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T16:07:33Z","timestamp":1739894853000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624015988"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["S0090955624015988"],"URL":"https:\/\/doi.org\/10.1124\/dmd.107.019265","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2008,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CYP2C19 Inhibition: The Impact of Substrate Probe Selection on in Vitro Inhibition Profiles","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.107.019265","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2008 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}